Neurocrine Biosciences Inc (NBIX)

Receivables turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 2,355,300 2,241,400 2,117,000 1,978,200 1,882,900 1,779,300 1,668,300 1,522,900 1,411,600 1,306,100 1,208,800 1,185,500 1,107,700 1,050,200 1,010,800 1,022,200 1,020,900 1,017,010 981,066 862,604
Receivables US$ in thousands 493,500 481,100 468,200 463,300 439,300 425,900 393,200 396,000 350,000 305,100 281,700 266,500 187,700 166,600 161,200 151,000 160,800 160,400 152,100 153,300
Receivables turnover 4.77 4.66 4.52 4.27 4.29 4.18 4.24 3.85 4.03 4.28 4.29 4.45 5.90 6.30 6.27 6.77 6.35 6.34 6.45 5.63

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $2,355,300K ÷ $493,500K
= 4.77

The receivables turnover ratio indicates how many times a company collects its accounts receivable during a specific period, reflecting the efficiency of its credit policies and ability to collect payments from customers.

For Neurocrine Biosciences Inc, the receivables turnover ratio fluctuated over the reported periods. The ratio was relatively stable around 6 times from March 31, 2020, to March 31, 2021, suggesting that the company was collecting its receivables efficiently during this time.

However, starting from March 31, 2022, the receivables turnover ratio began to decline gradually. This downward trend continued until December 31, 2024, reaching 4.77 times. A decreasing receivables turnover ratio could indicate that Neurocrine Biosciences Inc was experiencing difficulties in collecting payments from its customers, which might raise concerns about its liquidity and ability to effectively manage its accounts receivable.

It is advisable for investors and stakeholders to further investigate the reasons behind the declining receivables turnover ratio to assess the company's financial health and performance accurately.